Frazier Life Sciences led a $15m Series B funding round in Iolyx Therapeutics.

Frazier Life Sciences, a healthcare-focused venture capital investor, led a $15m Series B funding round in Iolyx Therapeutics, a clinical-stage biotechnology company developing ocular and autoimmune therapeutics, with participation from GC&H. “Our additional investment reflects continued conviction in Iolyx’s team, science, and strategy. The Phase 2 data in immune-driven dry eye provide a strong foundation for late-stage development, and this Series B financing and partnership will support Phase 3 readiness for ILYX-002 while enabling Iolyx to expand its pipeline into autoimmune-associated retinal diseases. We’re proud to back a company pairing rigorous clinical execution with a clear path to impact for patients who have long lacked targeted therapies,” Dan Estes, Frazier Life Sciences Partner.